ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,064.20
      0.91%
      US Tech 100
      17,178.00
      1.88%
      Dow Jones
      38,225.66
      0.85%
      Brent Oil
      83.815
      0.22%
      Bitcoin
      59,586.93
      0.79%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. OptiNose Inc (OPTN)

      7. OptiNose Inc (OPTN) News

      OPTN

      OptiNose (OPTN)

      OptiNose Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:OPTN
      DateTimeSourceHeadlineSymbolCompany
      2:07PMiHub NewswireFeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
      04/25/20247:00AMGlobeNewswire Inc.Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionNASDAQ:OPTNOptiNose Inc
      04/04/20244:01PMGlobeNewswire Inc.Optinose to Present at the Needham Virtual Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
      03/15/20243:34PMGlobeNewswire Inc.XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsNASDAQ:OPTNOptiNose Inc
      03/08/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OPTNOptiNose Inc
      03/07/20244:32PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OPTNOptiNose Inc
      03/07/20247:01AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OPTNOptiNose Inc
      03/07/20247:00AMGlobeNewswire Inc.Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:OPTNOptiNose Inc
      03/07/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OPTNOptiNose Inc
      02/29/20244:40PMGlobeNewswire Inc.Optinose Announces Reporting Date for Fourth Quarter 2023 Financial ResultsNASDAQ:OPTNOptiNose Inc
      02/29/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
      02/29/20244:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
      02/29/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
      02/29/20244:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
      02/23/20247:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OPTNOptiNose Inc
      02/22/20244:28PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OPTNOptiNose Inc
      02/14/20248:48PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OPTNOptiNose Inc
      02/13/20245:16PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OPTNOptiNose Inc
      02/01/20242:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
      01/30/20244:05PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OPTNOptiNose Inc
      01/18/202412:00PMGlobeNewswire Inc.Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In PracticeNASDAQ:OPTNOptiNose Inc
      12/21/20234:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OPTNOptiNose Inc
      12/20/202312:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
      12/20/202312:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
      12/06/20238:48AMDow Jones NewsOptinose Shares Slide Premarket as FDA Extends Xhance ReviewNASDAQ:OPTNOptiNose Inc
      12/06/20237:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OPTNOptiNose Inc
      12/06/20237:00AMGlobeNewswire Inc.Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCENASDAQ:OPTNOptiNose Inc
      11/22/20239:00AMGlobeNewswire Inc.Optinose to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
      11/09/20237:03AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OPTNOptiNose Inc
      11/09/20237:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OPTNOptiNose Inc
       Showing the most relevant articles for your search:NASDAQ:OPTN